Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $1.78 billion. The enterprise value is $1.15 billion.
| Market Cap | 1.78B |
| Enterprise Value | 1.15B |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 2.15 billion shares outstanding. The number of shares has increased by 15.75% in one year.
| Shares Outstanding | 2.15B |
| Shares Change (YoY) | +15.75% |
| Shares Change (QoQ) | +1.40% |
| Owned by Insiders (%) | 6.74% |
| Owned by Institutions (%) | 83.30% |
| Float | 1.12B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.46 |
| Forward PS | 8.30 |
| PB Ratio | 1.71 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.11, with a Debt / Equity ratio of 0.20.
| Current Ratio | 6.11 |
| Quick Ratio | 5.87 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,600.51 |
Financial Efficiency
Return on equity (ROE) is -65.40% and return on invested capital (ROIC) is -65.54%.
| Return on Equity (ROE) | -65.40% |
| Return on Assets (ROA) | -42.50% |
| Return on Capital (ROIC) | -65.54% |
| Revenue Per Employee | $206,449 |
| Profits Per Employee | -$733,062 |
| Employee Count | 1,218 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -71,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.15% in the last 52 weeks. The beta is 1.36, so DNA's price volatility has been higher than the market average.
| Beta (1Y) | 1.36 |
| 52-Week Price Change | -34.15% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 33.16 |
| Average Volume (30 Days) | 24,505,562 |
Short Selling Information
The latest short interest is 270.83 million, so 12.57% of the outstanding shares have been sold short.
| Short Interest | 270.83M |
| Short Previous Month | 255.72M |
| Short % of Shares Out | 12.57% |
| Short % of Float | 24.26% |
| Short Ratio (days to cover) | 11.02 |
Income Statement
In the last 12 months, DNA had revenue of $251.46 million and -$892.87 million in losses. Loss per share was -$0.46.
| Revenue | 251.46M |
| Gross Profit | 197.45M |
| Operating Income | -864.41M |
| Pretax Income | -892.94M |
| Net Income | -892.87M |
| EBITDA | -792.98M |
| EBIT | -892.85M |
| Loss Per Share | -$0.46 |
Balance Sheet
The company has $944.07 million in cash and $221.84 million in debt, giving a net cash position of $722.24 million or $0.34 per share.
| Cash & Cash Equivalents | 944.07M |
| Total Debt | 221.84M |
| Net Cash | 722.24M |
| Net Cash Per Share | $0.34 |
| Equity / Book Value | 1.10B |
| Book Value Per Share | 0.51 |
| Working Capital | 837.89M |
Cash Flow
In the last 12 months, operating cash flow was -$295.50 million and capital expenditures -$36.37 million, giving a free cash flow of -$331.87 million.
| Operating Cash Flow | -295.50M |
| Capital Expenditures | -36.37M |
| Free Cash Flow | -331.87M |
| FCF Per Share | -$0.17 |
Margins
Gross margin is 78.52%, with operating and profit margins of -343.76% and -355.08%.
| Gross Margin | 78.52% |
| Operating Margin | -343.76% |
| Pretax Margin | -355.11% |
| Profit Margin | -355.08% |
| EBITDA Margin | -315.36% |
| EBIT Margin | -355.07% |
| FCF Margin | -131.98% |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.75% |
| Shareholder Yield | -15.75% |
| Earnings Yield | -47.62% |
| FCF Yield | -17.70% |
Analyst Forecast
The average price target for DNA is $2.20, which is 165.48% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.20 |
| Price Target Difference | 165.48% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 35.23% |
| EPS Growth Forecast (5Y) | -26.16% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNA has an Altman Z-Score of -3.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.48 |
| Piotroski F-Score | 3 |